Literature DB >> 36267874

The long non-coding RNA SPRIGHTLY and its binding partner PTBP1 regulate exon 5 skipping of SMYD3 transcripts in group 4 medulloblastomas.

Bongyong Lee1,2, Keisuke Katsushima1,2, Rudramani Pokhrel1,2, Menglang Yuan1,2, Stacie Stapleton2, George Jallo2, Robert J Wechsler-Reya3, Charles G Eberhart1,4, Animesh Ray5,6, Ranjan J Perera1.   

Abstract

Background: Although some of the regulatory genes, signaling pathways, and gene regulatory networks altered in medulloblastomas (MB) are known, the roles of non-coding RNAs, particularly long non-coding RNAs (lncRNAs), are poorly described. Here we report that the lncRNA SPRIGHTLY (SPRY4-IT1) gene is upregulated in group 4 medulloblastoma (G4 MB).
Methods: SPRIGHTLY expression was assessed in MB subgroup patient-derived xenografts, cell lines, and patient samples. The effect of SPRIGHTLY hemizygous deletion on proliferation, invasion, apoptosis, and colony formation were assessed in vitro and on tumor growth in vivo. dChIRP pull-down assays were used to assess SPRIGHTLY-binding partners, confirmed by immunoprecipitation. SMYD3 ΔE5 transcripts were examined in cell lines and publicly available RNA-seq data. Pathway analysis was performed by phospho-kinase profiling and RNA-seq.
Results: CRISPR/Cas9 deletion of SPRIGHTLY reduced cell viability and invasion and increased apoptosis in G4 MB cell lines in vitro. SPRIGHTLY hemizygous-deleted G4 MB cells injected into mouse cerebellums produced smaller tumors than those derived from parental cells expressing both copies of SPRIGHTLY. SPRIGHTLY lncRNA bound to the intronic region of the SMYD3 pre-mRNA transcript. SPRIGHTLY also interacted with PTPB1 protein to regulate SMYD3 exon skipping to produce an aberrant protein. SPRIGHTLY-driven SMYD3 regulation enhanced the expression of EGFR pathway genes in G4 MB cell lines and activated cell coagulation/hemostasis-related gene expression, suggesting a novel oncogenic role in G4 MB. Conclusions: These results demonstrate the importance of SPRIGHTLY lncRNA as a promoter of G4 MB and the role of the SPRIGHTLY-SMYD3-PTPB1 axis as an important oncogenic regulator in MB.
© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.

Entities:  

Keywords:  PTPB1; SMYD3; SPRIGHTLY; long non-coding RNA; medulloblastoma

Year:  2022        PMID: 36267874      PMCID: PMC9569026          DOI: 10.1093/noajnl/vdac120

Source DB:  PubMed          Journal:  Neurooncol Adv        ISSN: 2632-2498


  63 in total

1.  Structural Basis for Substrate Preference of SMYD3, a SET Domain-containing Protein Lysine Methyltransferase.

Authors:  Weiqi Fu; Nan Liu; Qi Qiao; Mingzhu Wang; Jinrong Min; Bing Zhu; Rui-Ming Xu; Na Yang
Journal:  J Biol Chem       Date:  2016-02-29       Impact factor: 5.157

2.  The soft agar colony formation assay.

Authors:  Stanley Borowicz; Michelle Van Scoyk; Sreedevi Avasarala; Manoj Kumar Karuppusamy Rathinam; Jordi Tauler; Rama Kamesh Bikkavilli; Robert A Winn
Journal:  J Vis Exp       Date:  2014-10-27       Impact factor: 1.355

3.  Intertumoral Heterogeneity within Medulloblastoma Subgroups.

Authors:  Florence M G Cavalli; Marc Remke; Ladislav Rampasek; John Peacock; David J H Shih; Betty Luu; Livia Garzia; Jonathon Torchia; Carolina Nor; A Sorana Morrissy; Sameer Agnihotri; Yuan Yao Thompson; Claudia M Kuzan-Fischer; Hamza Farooq; Keren Isaev; Craig Daniels; Byung-Kyu Cho; Seung-Ki Kim; Kyu-Chang Wang; Ji Yeoun Lee; Wieslawa A Grajkowska; Marta Perek-Polnik; Alexandre Vasiljevic; Cecile Faure-Conter; Anne Jouvet; Caterina Giannini; Amulya A Nageswara Rao; Kay Ka Wai Li; Ho-Keung Ng; Charles G Eberhart; Ian F Pollack; Ronald L Hamilton; G Yancey Gillespie; James M Olson; Sarah Leary; William A Weiss; Boleslaw Lach; Lola B Chambless; Reid C Thompson; Michael K Cooper; Rajeev Vibhakar; Peter Hauser; Marie-Lise C van Veelen; Johan M Kros; Pim J French; Young Shin Ra; Toshihiro Kumabe; Enrique López-Aguilar; Karel Zitterbart; Jaroslav Sterba; Gaetano Finocchiaro; Maura Massimino; Erwin G Van Meir; Satoru Osuka; Tomoko Shofuda; Almos Klekner; Massimo Zollo; Jeffrey R Leonard; Joshua B Rubin; Nada Jabado; Steffen Albrecht; Jaume Mora; Timothy E Van Meter; Shin Jung; Andrew S Moore; Andrew R Hallahan; Jennifer A Chan; Daniela P C Tirapelli; Carlos G Carlotti; Maryam Fouladi; José Pimentel; Claudia C Faria; Ali G Saad; Luca Massimi; Linda M Liau; Helen Wheeler; Hideo Nakamura; Samer K Elbabaa; Mario Perezpeña-Diazconti; Fernando Chico Ponce de León; Shenandoah Robinson; Michal Zapotocky; Alvaro Lassaletta; Annie Huang; Cynthia E Hawkins; Uri Tabori; Eric Bouffet; Ute Bartels; Peter B Dirks; James T Rutka; Gary D Bader; Jüri Reimand; Anna Goldenberg; Vijay Ramaswamy; Michael D Taylor
Journal:  Cancer Cell       Date:  2017-06-12       Impact factor: 31.743

4.  Novel modes of splicing repression by PTB.

Authors:  Rachel Spellman; Christopher W J Smith
Journal:  Trends Biochem Sci       Date:  2006-01-05       Impact factor: 13.807

Review 5.  Biological basis of personalized anticoagulation in cancer: oncogene and oncomir networks as putative regulators of coagulopathy.

Authors:  Esterina D'Asti; Janusz Rak
Journal:  Thromb Res       Date:  2016-04       Impact factor: 3.944

6.  Novel lincRNA Discovery and Tissue-Specific Gene Expression across 30 Normal Human Tissues.

Authors:  Xianfeng Chen; Zhifu Sun
Journal:  Genes (Basel)       Date:  2021-04-21       Impact factor: 4.096

7.  Smyd3 regulates cancer cell phenotypes and catalyzes histone H4 lysine 5 methylation.

Authors:  Glenn S Van Aller; Nicolas Reynoird; Olena Barbash; Michael Huddleston; Shichong Liu; Anne-Flore Zmoos; Patrick McDevitt; Robert Sinnamon; BaoChau Le; Gloria Mas; Roland Annan; Julien Sage; Benjamin A Garcia; Peter J Tummino; Or Gozani; Ryan G Kruger
Journal:  Epigenetics       Date:  2012-04-01       Impact factor: 4.528

8.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples.

Authors:  Paul A Northcott; David J H Shih; Marc Remke; Yoon-Jae Cho; Marcel Kool; Cynthia Hawkins; Charles G Eberhart; Adrian Dubuc; Toumy Guettouche; Yoslayma Cardentey; Eric Bouffet; Scott L Pomeroy; Marco Marra; David Malkin; James T Rutka; Andrey Korshunov; Stefan Pfister; Michael D Taylor
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

9.  SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.

Authors:  Pawel K Mazur; Nicolas Reynoird; Purvesh Khatri; Pascal W T C Jansen; Alex W Wilkinson; Shichong Liu; Olena Barbash; Glenn S Van Aller; Michael Huddleston; Dashyant Dhanak; Peter J Tummino; Ryan G Kruger; Benjamin A Garcia; Atul J Butte; Michiel Vermeulen; Julien Sage; Or Gozani
Journal:  Nature       Date:  2014-05-21       Impact factor: 49.962

10.  Revealing long noncoding RNA architecture and functions using domain-specific chromatin isolation by RNA purification.

Authors:  Ibrahim A Ilik; Kun Qu; Plamen Georgiev; Jeffrey J Quinn; Ci Chu; Asifa Akhtar; Howard Y Chang
Journal:  Nat Biotechnol       Date:  2014-07-06       Impact factor: 54.908

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.